High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.
Bibliographical noteFunding Information:
Funding/Support and role of the sponsor: This work has been supported by the Anders Jahre Foundation , University of Oslo , Movember Foundation , South-Eastern Norway Regional Health Authority , Oslo University Hospital , and the Norwegian Research Council , whereas the urology biorepository for the ProMPT (Prostate Cancer Mechanisms of Progression and Treatment) study is funded by the CRUK Cambridge Centre urology malignancy programme and the Cambridge NIHR Biomedical Campus.
© 2020 The Author(s)
Copyright 2020 Elsevier B.V., All rights reserved.
- Leucine-rich α-2-glycoprotein 1
- Prostate cancer
ASJC Scopus subject areas